Generate:Biomedicines announced the unveiling of its cryogenic electron microscopy (CryoEM) laboratory in Andover, Massachusetts. Among the largest privately-owned CryoEM laboratories in the United States, this 70,000 sq ft site will enable scientists to visualize the molecular structure of proteins that are too small to be seen with traditional microscopes. As a result, the company will better understand the precise manner in which therapeutics interact with their intended targets, accelerating drug discovery processes and providing a competitive advantage in the de novo therapeutic protein field.
With the unveiling of this new CryoEM laboratory, the company will add a powerful new structural determination tool to the repertoire of its proprietary in-house machine learning models. By deploying CryoEM to explore novel proteins of interest, the new laboratory will yield terabytes of valuable data each day to add to the rapidly growing body of information available to The Generate Platform. And because The Generate Platform is learning from each new protein it produces and validates, the data generated by the CryoEM laboratory will ultimately contribute to the continuous improvement of the platform and its ability to create novel therapeutics.
“Our CryoEM laboratory in Andover will further strengthen our ability to produce large-scale structural data that will give The Generate Platform a strongly differentiated competitive advantage,” says Gevorg Grigoryan, PhD, co-founder and chief technology officer of Generate:Biomedicines. “By harnessing the power of CryoEM technology, we aim to open up new frontiers in our understanding of molecules, viruses, and other cellular components, helping us to tackle more complex biological questions and explore additional applications across modalities and therapeutic areas.”
“With the unveiling of our state-of-the-art CryoEM facility, we are excited to expand our footprint and are looking forward to leveraging these cutting-edge tools to execute on several current research programs,” said Adam Root, head of protein sciences at Generate:Biomedicines. “Equipped with four industry-leading microscopes, including foundational infrastructure, full end-to-end wet lab and ML-enabled data processing capabilities, this new laboratory demonstrates our growing maturity as a company and represents a critical milestone in our efforts to lead in the field of generative biology.”
SOURCE: Businesswire